Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trichostatin A in Relapsed or Refractory Hematologic Malignancies
NCT03838926Phase 1Recruiting
- Sponsor
- Vanda Pharmaceuticals Inc.
- Start
- Sep 2018
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of trichostatin a in hematologic malignancy, sponsored by Vanda Pharmaceuticals Inc. Primary endpoints: Adverse Events at 24 months, Dose-Limiting Toxicities at 24 months and 1 more. Started Sep 2018; status: recruiting.
02
Drugs
trichostatin a
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT03838926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03838926.